vs

Side-by-side financial comparison of AST SpaceMobile, Inc. (ASTS) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $54.3M, roughly 1.5× AST SpaceMobile, Inc.). PROCEPT BioRobotics Corp runs the higher net margin — -38.1% vs -136.2%, a 98.1% gap on every dollar of revenue. On growth, AST SpaceMobile, Inc. posted the faster year-over-year revenue change (2758.2% vs 20.2%).

AST SpaceMobile, Inc. is a publicly traded satellite designer and manufacturer based in Midland, Texas, United States. The company is building the SpaceMobile satellite constellation, a space-based cellular broadband network designed to connect directly to standard, unmodified smartphones. The network is intended to deliver 4G and 5G broadband coverage globally, particularly in remote and underserved regions.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

ASTS vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.5× larger
PRCT
$83.1M
$54.3M
ASTS
Growing faster (revenue YoY)
ASTS
ASTS
+2738.0% gap
ASTS
2758.2%
20.2%
PRCT
Higher net margin
PRCT
PRCT
98.1% more per $
PRCT
-38.1%
-136.2%
ASTS

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASTS
ASTS
PRCT
PRCT
Revenue
$54.3M
$83.1M
Net Profit
$-74.0M
$-31.6M
Gross Margin
64.9%
Operating Margin
-175.0%
-4.1%
Net Margin
-136.2%
-38.1%
Revenue YoY
2758.2%
20.2%
Net Profit YoY
-106.3%
-27.9%
EPS (diluted)
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTS
ASTS
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$54.3M
$76.4M
Q3 25
$14.7M
$83.3M
Q2 25
$79.2M
Q1 25
$69.2M
Q4 24
$68.2M
Q3 24
$58.4M
Q2 24
$53.4M
Net Profit
ASTS
ASTS
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$-74.0M
$-29.8M
Q3 25
$-122.9M
$-21.4M
Q2 25
$-19.6M
Q1 25
$-24.7M
Q4 24
$-18.9M
Q3 24
$-21.0M
Q2 24
$-25.6M
Gross Margin
ASTS
ASTS
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
ASTS
ASTS
PRCT
PRCT
Q1 26
-4.1%
Q4 25
-175.0%
-40.6%
Q3 25
-1109.0%
-27.8%
Q2 25
-28.0%
Q1 25
-39.7%
Q4 24
-28.9%
Q3 24
-38.4%
Q2 24
-50.3%
Net Margin
ASTS
ASTS
PRCT
PRCT
Q1 26
-38.1%
Q4 25
-136.2%
-39.1%
Q3 25
-833.7%
-25.7%
Q2 25
-24.7%
Q1 25
-35.8%
Q4 24
-27.6%
Q3 24
-35.9%
Q2 24
-48.0%
EPS (diluted)
ASTS
ASTS
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$-0.54
Q3 25
$-0.38
Q2 25
$-0.35
Q1 25
$-0.45
Q4 24
$-0.34
Q3 24
$-0.40
Q2 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTS
ASTS
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$4.3B
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$2.4B
$347.7M
Total Assets
$5.0B
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTS
ASTS
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$4.3B
$286.5M
Q3 25
$2.4B
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
ASTS
ASTS
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
ASTS
ASTS
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$2.4B
$365.9M
Q3 25
$1.6B
$380.3M
Q2 25
$385.8M
Q1 25
$389.2M
Q4 24
$402.2M
Q3 24
$241.2M
Q2 24
$251.8M
Total Assets
ASTS
ASTS
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$5.0B
$508.1M
Q3 25
$2.6B
$511.5M
Q2 25
$513.1M
Q1 25
$519.4M
Q4 24
$534.0M
Q3 24
$374.1M
Q2 24
$374.4M
Debt / Equity
ASTS
ASTS
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTS
ASTS
PRCT
PRCT
Operating Cash FlowLast quarter
$65.0M
Free Cash FlowOCF − Capex
$-330.7M
FCF MarginFCF / Revenue
-609.0%
Capex IntensityCapex / Revenue
728.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-790.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTS
ASTS
PRCT
PRCT
Q1 26
Q4 25
$65.0M
$-10.3M
Q3 25
$-64.5M
$-6.6M
Q2 25
$-15.0M
Q1 25
$-17.0M
Q4 24
$-32.4M
Q3 24
$-18.8M
Q2 24
$-15.7M
Free Cash Flow
ASTS
ASTS
PRCT
PRCT
Q1 26
Q4 25
$-330.7M
$-12.2M
Q3 25
$-302.9M
$-9.5M
Q2 25
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
Q3 24
$-19.0M
Q2 24
$-16.8M
FCF Margin
ASTS
ASTS
PRCT
PRCT
Q1 26
Q4 25
-609.0%
-15.9%
Q3 25
-2055.0%
-11.4%
Q2 25
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
Q3 24
-32.6%
Q2 24
-31.4%
Capex Intensity
ASTS
ASTS
PRCT
PRCT
Q1 26
Q4 25
728.7%
2.4%
Q3 25
1617.6%
3.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
1.7%
Q3 24
0.4%
Q2 24
2.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTS
ASTS

Products$44.4M82%
Other$7.8M14%
Sat Co$2.1M4%

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons